Alpha-GPC: What the Research Covers, Including a Stroke-Risk Study

By Erin Rose · Updated July 18, 2026 · Methodology

Educational overview — not medical advice. In some countries alpha-GPC (choline alfoscerate) is a prescription drug; nothing here should be read as a diagnosis or treatment recommendation. This statement has not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease.

On best Alpha-GPC, products are ranked by actual-mg disclosure first, cost per actual mg second — not by commissions.

Start here

What alpha-GPC is, and what has been studied

Alpha-GPC (alpha-glycerylphosphorylcholine) is a choline-donor compound: taken orally, it raises blood free-choline levels (Gatti 1992), the raw material the body uses to make acetylcholine, a neurotransmitter involved in memory, muscle contraction, and attention. That mechanism is established. It does not automatically show a benefit in a healthy adult taking a retail capsule. In some countries alpha-GPC (choline alfoscerate) is a prescription drug at higher doses than typical retail servings, studied in patient populations. That evidence does not transfer to a retail supplement, and it is a matter for a clinician, not a product page.

The research that applies to most retail buyers is a few small healthy-adult sports-performance trials at 250–630mg/day: a 6-day trial that measured isometric strength (Bellar 2015, n=13), a jump-power trial where the lower dose outperformed the higher one (Marcus 2017, n=48), and a trial that reported a Stroop-test difference at 630mg with no effect on three other cognitive tests or on growth hormone (Kerksick 2024, n=20 — whose lead author is a paid scientific advisor to the study's supplement sponsor, NNB Nutrition). These are small studies with mixed results.

The safety signal

Here is the fact that belongs at the top of any honest alpha-GPC page, not buried in a footnote: a 2021 study in JAMA Network Open followed 12,008,977 South Korean adults aged 50 and older for 10 years using national health-insurance claims data, and reported an association between alpha-GPC use and higher total stroke risk — adjusted hazard ratio 1.46 (95% CI 1.43–1.48), with risk increasing in a dose-response pattern as cumulative use rose (Lee et al. 2021). This is observational data: it demonstrates an association, not proven causation, and the study's authors do not identify a confirmed biological mechanism connecting alpha-GPC to stroke. It is also one of the largest population studies ever run on this compound, published in a major peer-reviewed journal. The honest frame is neither "alpha-GPC causes strokes" (unproven) nor silence — it's an observational signal that warrants a conversation with your doctor, especially if you have stroke risk factors.

The buying problem: the 50%-blend label trap

Alpha-GPC is most commonly manufactured and sold as a 50%-standardized powder on a carrier (mannitol or silica), because pure alpha-GPC is a hygroscopic oil that's genuinely difficult to encapsulate directly. Double Wood's own product page is the one brand in this comparison that explicitly shows that math: "600mg of standardized Alpha GPC 50%" per 2-capsule serving means 300mg is the actual compound. Nutricost, NOW, Sports Research, and Jarrow each print a single "Alpha-GPC Xmg" figure without disclosing whether that's raw-material weight or actual-compound weight — so a shopper comparing "300mg" across five brands cannot assume they're getting the same actual alpha-GPC content. That's a category-wide transparency gap, not evidence any specific brand is underdosing you; see the ranking on best Alpha-GPC.

Frequently asked questions

Related guides

• Phosphatidylserine
• CoQ10
• Omega-3
• NMN
• Citicoline vs. Alpha-GPC

Sources